GlassScriptPhysician profile
Rajiv Saini
NPI 1699724088
$4,859.94
in general payments reported to CMS, 2019-2025
38 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $323 · 2021: $371 · 2022: $614 · 2023: $556 · 2024: $647 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.97 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $612.64 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $512.51 | 2019-2025 | Erleada, Akeega |
| Neotract INC. | $447.64 | 2019-2020 | |
| Procept Biorobotics Corporation | $447.10 | 2019-2024 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $342.26 | 2019-2025 | Axonics, Rezum Generator |
| Teleflex LLC | $312.53 | 2021-2025 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $251.01 | 2019-2025 | |
| Medtronic, INC. | $239.98 | 2021-2023 | Interstim |
| Antares Pharma, INC. | $227.47 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Dendreon Pharmaceuticals LLC | $144.14 | 2019-2023 | Provenge |
| Amgen INC. | $121.34 | 2024 | Repatha |
| Pfizer INC. | $104.63 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $99.69 | 2023-2025 | Orgovyx, Gemtesa |
| Urovant Sciences INC | $80.32 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $70.26 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $62.12 | 2023-2024 | |
| Myovant Sciences INC. | $60.95 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $53.07 | 2025 | Adstiladrin |
| Allergan, INC. | $51.79 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $51.25 | 2022 | |
| Abbvie INC. | $50.44 | 2019-2021 | |
| Telix Pharmaceuticals | $49.88 | 2024-2025 | Illuccix |
| Blue Earth Diagnostics | $47.00 | 2019-2020 | |
| Endo USA, INC. | $42.24 | 2025 | Aveed, Xiaflex |
| Hollister Incorporated | $41.63 | 2019-2022 | |
| Dentsply Ih Ab | $40.30 | 2024-2025 | Lofric |
| Acerus Pharmaceuticals Corporation | $39.24 | 2022 | |
| Axonics, INC. | $36.04 | 2022-2024 | Bulkamid |
| Coloplast Corp | $32.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $31.36 | 2025 | |
| Laborie Medical Technologies Corp. | $27.43 | 2023 | |
| Olympus America INC. | $23.64 | 2023 | Itind System |
| Bluewind Medical | $19.87 | 2024 | |
| Accord Healthcare, INC. | $19.68 | 2023 | |
| Merck Sharp & Dohme LLC | $19.15 | 2022 | |
| Endo Pharmaceuticals INC. | $17.94 | 2019 | |
| Clarus Therapeutics INC. | $17.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.